{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T15:27:40Z","timestamp":1771255660440,"version":"3.50.1"},"reference-count":273,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Almost half of patients with triple-negative breast cancer (TNBC) develop brain metastasis (TNBCBM), a marker of poor prognosis. TNBC is a more aggressive breast cancer subtype which lacks ER, PR, and HER2 expression, and thus, exploring predictive biomarkers is crucial to improving TNBCBM outcomes through targeted therapy. To curate these biomarkers, peer-reviewed publications from 2010 to 2025 were extracted from PubMed, Scopus, Embase, Cochrane, and Web of Science if they evaluated clinicopathological biomarkers of TNBCBM. A total of 130 studies (60 clinical and 70 pre-clinical) were included. Publications most often featured transcriptomic studies, growth factor receptors, and immune microenvironment markers with 37, 19, and 17 studies identified, respectively. While TNBC aggressiveness has been linked to metastasis, advancing stage, and poor prognosis, several studies focused on utilizing circulating protein and transcriptomic biomarkers for early detection. While few pathways appeared specifically for TNBCBM, investigating these biomarkers further may allow for improved risk stratification, clinical trial design, patient selection, and therapeutic development. Identification of the most promising biomarkers will pave the way for improved prognosis of the most lethal complications of TNBC.<\/jats:p>","DOI":"10.3390\/ijms27041909","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T14:55:47Z","timestamp":1771253747000},"page":"1909","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular and Clinicopathological Biomarkers Predicting Brain Metastasis in Triple-Negative Breast Cancer: A Systematic Review"],"prefix":"10.3390","volume":"27","author":[{"given":"Savi","family":"Agarwal","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, University of California, Los Angeles, CA 90095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasha","family":"Mehranpour","sequence":"additional","affiliation":[{"name":"School of Medicine, California University of Science and Medicine, 1501 Violet Street, Colton, CA 92324, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjani","family":"Chawla","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carissa","family":"Vaish","sequence":"additional","affiliation":[{"name":"School of Public Health, University of Washington, Seattle, WA 98195, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of California, Los Angeles, CA 90095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5176-5615","authenticated-orcid":false,"given":"Isaac","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of California, Los Angeles, CA 90095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8514-2021","authenticated-orcid":false,"given":"Madhuri","family":"Wadehra","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2147\/OTT.S293685","article-title":"Understanding Patterns of Brain Metastasis in Triple-Negative Breast Cancer and Exploring Potential Therapeutic Targets","volume":"14","author":"Lv","year":"2021","journal-title":"OTT"},{"key":"ref_2","unstructured":"Anders, C., and Carey, L.A. (2008). Understanding and Treating Triple-Negative Breast Cancer. Oncology, 22, 1233\u20131239; discussion 1239\u20131240, 1243."},{"key":"ref_3","first-page":"7","article-title":"Cancer Statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10549-016-4059-6","article-title":"Triple-Negative Breast Cancer Has Worse Overall Survival and Cause-Specific Survival than Non-Triple-Negative Breast Cancer","volume":"161","author":"Li","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kesireddy, M., Elsayed, L., Shostrom, V.K., Agarwal, P., Asif, S., Yellala, A., and Krishnamurthy, J. (2024). Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis. Cancers, 16.","DOI":"10.20944\/preprints202404.1138.v1"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-012-2243-x","article-title":"Brain Metastases after Breast-Conserving Therapy and Systemic Therapy: Incidence and Characteristics by Biologic Subtype","volume":"136","author":"Arvold","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1097\/JS9.0000000000001799","article-title":"Global biomarker trends in triple-negative breast cancer research: A bibliometric analysis","volume":"110","author":"Wang","year":"2024","journal-title":"Int. J. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.6026\/973206300212245","article-title":"Molecular markers in triple-negative breast cancer: A retrospective correlation study","volume":"21","author":"Gupta","year":"2025","journal-title":"BioInformation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1200\/OP.23.00794","article-title":"Breast Cancer Brain Metastasis: A Comprehensive Review","volume":"20","author":"Raghavendra","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/tbj.13230","article-title":"Treatment Response as Predictor for Brain Metastasis in Triple Negative Breast Cancer: A Score-Based Model","volume":"25","author":"Gabani","year":"2019","journal-title":"Breast J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"8540","DOI":"10.1002\/cam4.3449","article-title":"A Risk Stratification Model for Predicting Brain Metastasis and Brain Screening Benefit in Patients with Metastatic Triple-Negative Breast Cancer","volume":"9","author":"Lin","year":"2020","journal-title":"Cancer Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.4103\/jcrt.jcrt_2079_21","article-title":"Risk Factors and Prognostic Factors of Brain Metastasis of Triple-Negative Breast Cancer: A Single-Center Retrospective Study","volume":"20","author":"He","year":"2024","journal-title":"J. Cancer Res. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2715723","DOI":"10.21037\/gs-21-537","article-title":"A Pre-Operative MRI-Based Brain Metastasis Risk-Prediction Model for Triple-Negative Breast Cancer","volume":"10","author":"Cheng","year":"2021","journal-title":"Gland. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S658","DOI":"10.1016\/j.annonc.2022.07.303","article-title":"264P Increased Membrane HER3 Expression in Brain Metastases Compared to Primary Tumors in Breast Cancer","volume":"33","author":"Kusuhara","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Wu, F., McCuaig, R.D., Sutton, C.R., Tan, A.H.Y., Jeelall, Y., Bean, E.G., Dai, J., Prasanna, T., Batham, J., and Malik, L. (2019). Nuclear-Biased DUSP6 Expression Is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20123080"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1758835920946259","DOI":"10.1177\/1758835920946259","article-title":"Clinicopathologic Significance of Nuclear HER4 and Phospho-YAP(S127) in Human Breast Cancers and Matching Brain Metastases","volume":"12","author":"Lim","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10549-022-06783-1","article-title":"EGFR as a Potent CAR T Target in Triple Negative Breast Cancer Brain Metastases","volume":"197","author":"Subham","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ajpath.2013.03.023","article-title":"Frequent Genetic Alterations in EGFR- and HER2-Driven Pathways in Breast Cancer Brain Metastases","volume":"183","author":"Hohensee","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2174\/1566524020666201120142717","article-title":"ProBDNF Is a Novel Mediator of the Interaction Between MDA-MB- 231 Breast Cancer Cells and Brain Microvascular Endothelial Cells","volume":"21","author":"Alhusban","year":"2021","journal-title":"Curr. Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e569","DOI":"10.1016\/j.clbc.2020.04.001","article-title":"RANKLed by the Complexity of Signaling in Breast Cancer Metastasis to the Brain","volume":"20","author":"Wang","year":"2020","journal-title":"Clin. Breast Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"44254","DOI":"10.18632\/oncotarget.5471","article-title":"FN14 and GRP94 Expression Are Prognostic\/Predictive Biomarkers of Brain Metastasis Outcome That Open up New Therapeutic Strategies","volume":"6","author":"Guney","year":"2015","journal-title":"Oncotarget"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1016\/j.ijrobp.2020.07.958","article-title":"Final Results of a Prospective Correlative Analysis of Circulating Tumor Cells and Early Distant Brain Failure after Stereotactic Radiotherapy\/Radiosurgery for Brain Metastases of Breast Cancer","volume":"108","author":"Castro","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13058-019-1184-2","article-title":"Clonality of Circulating Tumor Cells in Breast Cancer Brain Metastasis Patients","volume":"21","author":"Riebensahm","year":"2019","journal-title":"Breast Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Maji, S., Leitch, A.M., Akopova, I., Nguyen, P., and Vishwanatha, J.K. (2015). Abstract B26: Role of Exosomal Annexin A2 in Angiogenesis and Breast Cancer Metastasis. Mol. Cancer Ther., 14.","DOI":"10.1158\/1538-8514.TUMANG15-B26"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10549-017-4135-6","article-title":"Role of HYAL1 Expression in Primary Breast Cancer in the Formation of Brain Metastases","volume":"162","author":"Witzel","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1200\/JCO.2024.42.16_suppl.1018","article-title":"Genomic and Tumor Microenvironment Dynamics of Brain Metastases in Breast Cancer","volume":"42","author":"Manogna","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/bjc.2011.464","article-title":"High Frequency of Complex TP53 Mutations in CNS Metastases from Breast Cancer","volume":"106","author":"Vivenza","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1200\/JCO.2020.38.15_suppl.2525","article-title":"Genomic Profiling of Breast Cancer Brain Metastases Reveals Targetable Alterations","volume":"38","author":"Kabraji","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/bjc.2017.224","article-title":"Novel Immunohistochemistry-Based Signatures to Predict Metastatic Site of Triple-Negative Breast Cancers","volume":"117","author":"Klimov","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Morikawa, A., Robinson, D., Soellner, M., Wu, Y.-M., Lonigro, R., Gilani, R., Cheng, X., Lachacz, E., Thomas, D., and McMurray, K. (2019). Abstract PD9-12: Integrative Molecular Profiling of Breast Cancer Brain Metastasis and Patient-Derived Xenograft Organoids from Resected Breast Cancer Brain Metastases to Interrogate and Prioritize Therapeutic Personalized Strategies. Cancer Res., 79.","DOI":"10.1158\/1538-7445.SABCS18-PD9-12"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/onco.13855","article-title":"Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases","volume":"26","author":"Huang","year":"2021","journal-title":"Oncologist"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"16129","DOI":"10.1002\/cam4.6267","article-title":"Risk of Metastasis in BRCA2 Carriers Diagnosed with Triple-Negative Breast Cancer","volume":"12","author":"Moreno","year":"2023","journal-title":"Cancer Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10549-025-07705-7","article-title":"Brain Metastases in Patients with Metastatic Breast Cancer and BRCA1\/2 Mutations in Cell-Free DNA","volume":"212","author":"Vidula","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Wikman, H., Sielaff-Frimpong, B., Kropidlowski, J., Witzel, I., Milde-Langosch, K., Sauter, G., Westphal, M., Lamszus, K., and Pantel, K. (2012). Clinical Relevance of Loss of 11p15 in Primary and Metastatic Breast Cancer: Association with Loss of PRKCDBP Expression in Brain Metastases. PloS ONE, 7.","DOI":"10.1371\/journal.pone.0047537"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10549-021-06364-8","article-title":"Genomic Profiling Using the UltraSEEK Panel Identifies Discordancy between Paired Primary and Breast Cancer Brain Metastases and an Association with Brain Metastasis-Free Survival","volume":"190","author":"Giannoudis","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Huang, Q.F., Fang, D.L., Nong, B.B., and Zeng, J. (2021). Focal Pyroptosis-Related Genes AIM2 and ZBP1 Are Prognostic Markers for Triple-Negative Breast Cancer with Brain Metastases. Transl. Cancer Res., 10.","DOI":"10.21037\/tcr-21-2182"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Galego, S., Kauppila, L.A., Malh\u00f3, R., Pimentel, J., and Brito, M.A. (2021). Myocyte Enhancer Factor 2C as a New Player in Human Breast Cancer Brain Metastases. Cells, 10.","DOI":"10.3390\/cells10020378"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Hamester, F., St\u00fcrken, C., Saygi, C., Qi, M., Legler, K., Gorzelanny, C., Robador, J.R., Schmalfeldt, B., Laakmann, E., and M\u00fcller, V. (2022). Insights into the Steps of Breast Cancer\u2013Brain Metastases Development: Tumor Cell Interactions with the Blood\u2013Brain Barrier. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031900"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/1535-7163.MCT-10-1089","article-title":"PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer","volume":"10","author":"Sahin","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1186\/bcr3071","article-title":"Phosphatidylinositol 3-Kinase Pathway Activation in Breast Cancer Brain Metastases","volume":"13","author":"Adamo","year":"2011","journal-title":"Breast Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.18632\/oncotarget.14047","article-title":"PTEN Mediates the Cross Talk between Breast and Glial Cells in Brain Metastases Leading to Rapid Disease Progression","volume":"8","author":"Hohensee","year":"2016","journal-title":"Oncotarget"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13046-025-03312-y","article-title":"Targeting TUBB2B Inhibits Triple-Negative Breast Cancer Growth and Brain-Metastatic Colonization","volume":"44","author":"He","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"De Lara, S., Nyqvist, J., Werner R\u00f6nnerman, E., Helou, K., Kenne Sarenmalm, E., Einbeigi, Z., Karlsson, P., Parris, T.Z., and Kov\u00e1cs, A. (2019). The Prognostic Relevance of FOXA1 and Nestin Expression in Breast Cancer Metastases: A Retrospective Study of 164 Cases during a 10-Year Period (2004\u20132014). BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5373-2"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1066896921990717","article-title":"Cytokeratin 7, GATA3, and SOX-10 Is a Comprehensive Panel in Diagnosing Triple Negative Breast Cancer Brain Metastases","volume":"29","author":"Statz","year":"2021","journal-title":"Int. J. Surg. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"23548","DOI":"10.1038\/s41598-021-02903-x","article-title":"Discordance of PIK3CA and TP53 Mutations between Breast Cancer Brain Metastases and Matched Primary Tumors","volume":"11","author":"Thulin","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/cac2.12102","article-title":"Mutational Characteristics Determined Using Circulating Tumor DNA Analysis in Triple-Negative Breast Cancer Patients with Distant Metastasis","volume":"40","author":"Rong","year":"2020","journal-title":"Cancer Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3332\/ecancer.2019.891","article-title":"Proteomics Characterisation of Central Nervous System Metastasis Biomarkers in Triple Negative Breast Cancer","volume":"13","author":"Rojas","year":"2019","journal-title":"ecancermedicalscience"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/1535-7163.MCT-19-0461","article-title":"Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis\u2013Initiating Cells","volume":"19","author":"Yamashita","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"P3-07\u201327","DOI":"10.1158\/1538-7445.SABCS15-P3-07-27","article-title":"Abstract P3-07-27: Distinct Biomarker Features in Triple-Negative Breast Cancer Metastases to the Brain, Liver and Bone","volume":"76","author":"Xiu","year":"2016","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"pkz063","DOI":"10.1093\/jncics\/pkz063","article-title":"PTHrP, A Biomarker for CNS Metastasis in Triple-Negative Breast Cancer and Selection for Adjuvant Chemotherapy in Node-Negative Disease","volume":"4","author":"Assaker","year":"2020","journal-title":"JNCI Cancer Spectr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12935-023-02896-9","article-title":"The Role of the Desmosomal Protein Desmocollin 2 in Tumour Progression in Triple Negative Breast Cancer Patients","volume":"23","author":"Reimer","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.3892\/or.2016.4710","article-title":"Inhibition of \u03922-Adrenergic Receptor Reduces Triple-Negative Breast Cancer Brain Metastases: The Potential Benefit of Perioperative \u03b2-Blockade","volume":"35","author":"Choy","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s10238-022-00880-7","article-title":"Overexpression in Metastatic Breast Cancer Supports Syndecan-1 as a Marker of Invasiveness and Poor Prognosis","volume":"23","author":"Cerbelli","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e010782","DOI":"10.1136\/jitc-2024-010782","article-title":"UBE2T\/CDC42\/CD276 Signaling Axis Mediates Brain Metastasis of Triple-Negative Breast Cancer via Lysosomal Autophagy","volume":"13","author":"Shi","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40659-020-00311-5","article-title":"MiR-128 Suppresses Metastatic Capacity by Targeting Metadherin in Breast Cancer Cells","volume":"53","author":"Cao","year":"2020","journal-title":"Biol. Res."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Cheng, S.-W., Chen, P.-C., Lin, M.-H., Ger, T.-R., Chiu, H.-W., and Lin, Y.-F. (2021). GBP5 Repression Suppresses the Metastatic Potential and PD-L1 Expression in Triple-Negative Breast Cancer. Biomedicines, 9.","DOI":"10.3390\/biomedicines9040371"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/j.humpath.2013.03.010","article-title":"Metastatic Triple-Negative Breast Cancers at First Relapse Have Fewer Tumor-Infiltrating Lymphocytes than Their Matched Primary Breast Tumors: A Pilot Study","volume":"44","author":"Ye","year":"2013","journal-title":"Hum. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Joshi, V., Beecher, K., Lim, M., Stacey, A., Feng, Y., Jat, P.S., Duijf, P.H.G., Simpson, P.T., Lakhani, S.R., and McCart Reed, A.E. (2024). B7-H3 Expression in Breast Cancer and Brain Metastasis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073976"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10549-019-05211-1","article-title":"Examination and Prognostic Implications of the Unique Microenvironment of Breast Cancer Brain Metastases","volume":"176","author":"Sambade","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.3390\/curroncol28030204","article-title":"Abstracts of the 2021 Canadian Association of Medical Oncologists Annual Meeting","volume":"28","author":"Loree","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-017-4526-8","article-title":"Discrepancies between Biomarkers of Primary Breast Cancer and Subsequent Brain Metastases: An International Multicenter Study","volume":"167","author":"Meattini","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/PAI.0000000000000952","article-title":"Androgen Receptor Is Expressed in Breast Cancer Brain Metastases","volume":"29","author":"Bergen","year":"2021","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Jiaxin, C., Jinmei, Z., Huiqiang, Z., Xuexue, W., Xiaobo, W., Shaohua, Z., Yanhong, T., Zefei, J., and Tao, W. (2022). Conversion of ER, PR, HER2 and Ki-67 and Prognosis in Breast Cancer Metastases to the Brain. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.1002173"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"15014","DOI":"10.1038\/npjbcancer.2015.14","article-title":"\u03b1B-Crystallin Expression in Breast Cancer Is Associated with Brain Metastasis","volume":"1","author":"Voduc","year":"2015","journal-title":"npj Breast Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Jung, Y.Y., Kim, H.M., and Koo, J.S. (2015). Expression of Lipid Metabolism-Related Proteins in Metastatic Breast Cancer. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137204"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.1038\/s41467-020-20144-w","article-title":"HIF1A Signaling Selectively Supports Proliferation of Breast Cancer in the Brain","volume":"11","author":"Ebright","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"100775","DOI":"10.1016\/j.tranon.2020.100775","article-title":"Hypomethylating Agent Azacitidine Is Effective in Treating Brain Metastasis Triple-Negative Breast Cancer Through Regulation of DNA Methylation of Keratin 18 Gene","volume":"13","author":"Butler","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/neuonc\/noz198","article-title":"GRP94 Promotes Brain Metastasis by Engaging Pro-Survival Autophagy","volume":"22","author":"Foj","year":"2020","journal-title":"Neuro Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Blackman, M.C.N.M., Capeloa, T., Rondeau, J.D., Zampieri, L.X., Benyahia, Z., Van de Velde, J.A., Fransolet, M., Daskalopoulos, E.P., Michiels, C., and Beauloye, C. (2022). Mitochondrial Protein Cox7b Is a Metabolic Sensor Driving Brain-Specific Metastasis of Human Breast Cancer Cells. Cancers, 14.","DOI":"10.3390\/cancers14184371"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11060-018-2959-5","article-title":"Expression of LC3B and FIP200\/Atg17 in Brain Metastases of Breast Cancer","volume":"140","author":"Ulasov","year":"2018","journal-title":"J. Neurooncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10585-016-9835-5","article-title":"In Vivo Magnetic Resonance Imaging Investigating the Development of Experimental Brain Metastases Due to Triple Negative Breast Cancer","volume":"34","author":"Hamilton","year":"2017","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Debeb, B.G., Lacerda, L., Anfossi, S., Diagaradjane, P., Chu, K., Huo, L., Wei, C., Larson, R., Wolfe, A., and Xu, W. (2015). Abstract 3087: MicroRNA 141: A Novel Regulator of Brain Metastasis from Breast Cancer. Cancer Res., 75.","DOI":"10.1158\/1538-7445.AM2015-3087"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2147\/BCTT.S372083","article-title":"miR-623 Targets Metalloproteinase-1 and Attenuates Extravasation of Brain Metastatic Triple-Negative Breast Cancer Cells","volume":"14","author":"Hammash","year":"2022","journal-title":"BCTT"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/s41388-021-01654-3","article-title":"MiR-211 Determines Brain Metastasis Specificity through SOX11\/NGN2 Axis in Triple-Negative Breast Cancer","volume":"40","author":"Pan","year":"2021","journal-title":"Oncogene"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Figueira, I., Godinho-Pereira, J., Galego, S., Maia, J., Hask\u00f3, J., Moln\u00e1r, K., Malh\u00f3, R., Costa-Silva, B., Wilhelm, I., and Krizbai, I.A. (2021). MicroRNAs and Extracellular Vesicles as Distinctive Biomarkers of Precocious and Advanced Stages of Breast Cancer Brain Metastases Development. Int. J. Mol. Sci., 22.","DOI":"10.37247\/PAMOL2ED.2.2021.40"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10549-021-06255-y","article-title":"Combinatorial Targeting of microRNA-26b and microRNA-101 Exerts a Synergistic Inhibition on Cyclooxygenase-2 in Brain Metastatic Triple-Negative Breast Cancer Cells","volume":"187","author":"Harati","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/1878-0261.12632","article-title":"Downregulation of Circulating miR 802-5p and miR 194-5p and Upregulation of Brain MEF2C along Breast Cancer Brain Metastasization","volume":"14","author":"Sereno","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"216508","DOI":"10.1016\/j.canlet.2023.216508","article-title":"A Novel Axis of circKIF4A-miR-637-STAT3 Promotes Brain Metastasis in Triple-Negative Breast Cancer","volume":"581","author":"Wu","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"217734","DOI":"10.1016\/j.canlet.2025.217734","article-title":"Isoliquiritigenin Reduces Brain Metastasis by circNAV3-ST6GALNAC5-EGFR Axis in Triple-Negative Breast Cancer","volume":"624","author":"Xie","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_80","first-page":"265","article-title":"Brain-Metastatic Triple-Negative Breast Cancer Cells Regain Growth Ability by Altering Gene Expression Patterns","volume":"10","author":"Choi","year":"2013","journal-title":"Cancer Genom. Proteom."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1158\/1078-0432.CCR-21-0361","article-title":"IL13R\u03b12 Promotes Proliferation and Outgrowth of Breast Cancer Brain Metastases","volume":"27","author":"Tesic","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Liu, Y., Smith, M.R., Wang, Y., D\u2019Agostino, R., Ruiz, J., Lycan, T., Kucera, G.L., Miller, L.D., Li, W., and Chan, M.D. (2023). C-Met Mediated Cytokine Network Promotes Brain Metastasis of Breast Cancer by Remodeling Neutrophil Activities. Cancers, 15.","DOI":"10.3390\/cancers15092626"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Thies, K.A., Hammer, A.M., Hildreth, B.E., Russell, L.O., Sizemore, S.T., Trimboli, A.J., Kladney, R.D., Bolyard, C.M., Pilarski, R., and Schoenfield, L. (2018). Abstract 49: Stromal Platelet Derived Growth Factor Receptor (PDGFR\u03b2) Signaling: A Novel Therapeutic Target for Breast Cancer Brain Metastasis (BCBM). Cancer Res., 78.","DOI":"10.1158\/1538-7445.AM2018-49"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s42003-024-06200-x","article-title":"Brain Endothelial Cells Promote Breast Cancer Cell Extravasation to the Brain via EGFR-DOCK4-RAC1 Signalling","volume":"7","author":"Galloni","year":"2024","journal-title":"Commun. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41698-019-0094-1","article-title":"Interaction of Tumor Cells and Astrocytes Promotes Breast Cancer Brain Metastases through TGF-\u03922\/ANGPTL4 Axes","volume":"3","author":"Gong","year":"2019","journal-title":"npj Precis. Onc."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13058-018-1020-0","article-title":"NOTCH3 Expression Is Linked to Breast Cancer Seeding and Distant Metastasis","volume":"20","author":"Leontovich","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e138928","DOI":"10.1172\/jci.insight.138928","article-title":"Role of C-Met\/\u03b21 Integrin Complex in the Metastatic Cascade in Breast Cancer","volume":"6","author":"Lau","year":"2021","journal-title":"JCI Insight"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1940-6207.CAPR-14-0225","article-title":"A Novel Preclinical Method to Quantitatively Evaluate Early-Stage Metastatic Events at the Murine Blood\u2013Brain Barrier","volume":"8","author":"Adkins","year":"2015","journal-title":"Cancer Prev. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1535-7163.MCT-18-1176","article-title":"Development of Therapeutic Anti-JAGGED1 Antibodies for Cancer Therapy","volume":"18","author":"Masiero","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1002\/1878-0261.70022","article-title":"ShcD Adaptor Protein Drives Invasion of Triple Negative Breast Cancer Cells by Aberrant Activation of EGFR Signaling","volume":"19","author":"Lau","year":"2025","journal-title":"Mol. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1158\/1541-7786.MCR-24-0494","article-title":"Insulin Resistance Increases TNBC Aggressiveness and Brain Metastasis via Adipocyte-Derived Exosomes","volume":"23","author":"Qiu","year":"2025","journal-title":"Mol. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/path.4304","article-title":"Angiopoietin-2 Mediates Blood\u2013Brain Barrier Impairment and Colonization of Triple-Negative Breast Cancer Cells in Brain","volume":"232","author":"Avraham","year":"2014","journal-title":"J. Pathol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/path.6319","article-title":"Nerve Growth Factor Inducible (VGF) Is a Secreted Mediator for Metastatic Breast Cancer Tropism to the Brain","volume":"264","author":"Carvalho","year":"2024","journal-title":"J. Pathol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/jcar.JCar_20_20","article-title":"Angiopoietin-like Protein 4 Is a Chromatin-Bound Protein That Enhances Mammosphere Formation in Vitro and Experimental Triple-Negative Breast Cancer Brain and Liver Metastases in Vivo","volume":"20","author":"Simeon","year":"2021","journal-title":"J. Carcinog."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/1878-0261.12752","article-title":"Pericyte-Secreted IGF2 Promotes Breast Cancer Brain Metastasis Formation","volume":"14","author":"Fazakas","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1158\/0008-5472.CAN-19-2961","article-title":"Proteomic Profiling of the ECM of Xenograft Breast Cancer Metastases in Different Organs Reveals Distinct Metastatic Niches","volume":"80","author":"Hebert","year":"2020","journal-title":"Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s40164-023-00463-6","article-title":"ProNGF Promotes Brain Metastasis through TrkA\/EphA2 Induced Src Activation in Triple Negative Breast Cancer Cells","volume":"12","author":"Cicero","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_98","first-page":"34","article-title":"RARRES2 Regulates Lipid Metabolic Reprogramming to Mediate the Development of Brain Metastasis in Triple Negative Breast Cancer","volume":"10","author":"Li","year":"2023","journal-title":"Mil. Med. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.ccell.2024.08.015","article-title":"Distinct Tumor Architectures and Microenvironments for the Initiation of Breast Cancer Metastasis in the Brain","volume":"42","author":"Gan","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1038\/s41467-018-07406-4","article-title":"High-Resolution Clonal Mapping of Multi-Organ Metastasis in Triple Negative Breast Cancer","volume":"9","author":"Echeverria","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"45828","DOI":"10.1038\/srep45828","article-title":"A 3q Gene Signature Associated with Triple Negative Breast Cancer Organ Specific Metastasis and Response to Neoadjuvant Chemotherapy","volume":"7","author":"Qian","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-17-2994","article-title":"Targeting Brain-Adaptive Cancer Stem Cells Prohibits Brain Metastatic Colonization of Triple-Negative Breast Cancer","volume":"78","author":"Ren","year":"2018","journal-title":"Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/s41556-024-01446-3","article-title":"Loss of Kmt2c or Kmt2d Drives Brain Metastasis via KDM6A-Dependent Upregulation of MMP3","volume":"26","author":"Seehawer","year":"2024","journal-title":"Nat. Cell Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"108454","DOI":"10.1016\/j.intimp.2021.108454","article-title":"CXCL8 Is a Prognostic Biomarker and Correlated with TNBC Brain Metastasis and Immune Infiltration","volume":"103","author":"Shen","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Sun, X., Yang, N., Zhou, X., Dai, H., Li, Q., Feng, A., Xu, G., Liu, Y., Xu, L., and Zhang, Z. (2022). CILP, a Putative Gene Associated With Immune Infiltration in Breast Cancer Brain Metastases. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.862264"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Woditschka, S., Palmieri, D., Duchnowska, R., Jassem, J., Badve, S., Sledge, G.W., and Steeg, P.S. (2012). Abstract 5306: Overexpression of RAD51 Promotes Brain Metastases from Breast Cancer. Cancer Res., 72.","DOI":"10.1158\/1538-7445.AM2012-5306"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1158\/0008-5472.CAN-18-3264","article-title":"EN1 Is a Transcriptional Dependency in Triple-Negative Breast Cancer Associated with Brain Metastasis","volume":"79","author":"Peluffo","year":"2019","journal-title":"Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41388-019-0959-3","article-title":"TGLI1 Transcription Factor Mediates Breast Cancer Brain Metastasis via Activating Metastasis-Initiating Cancer Stem Cells and Astrocytes in the Tumor Microenvironment","volume":"39","author":"Sirkisoon","year":"2020","journal-title":"Oncogene"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Dion\u00edsio, M.R., Vieira, A.F., Carvalho, R., Conde, I., Oliveira, M., Gomes, M., Pinto, M.T., Pereira, P., Pimentel, J., and Souza, C. (2020). BR-BCSC Signature: The Cancer Stem Cell Profile Enriched in Brain Metastases That Predicts a Worse Prognosis in Lymph Node-Positive Breast Cancer. Cells, 9.","DOI":"10.3390\/cells9112442"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11306-021-01864-6","article-title":"Metabolite Profiling Reveals a Connection between Aldehyde Dehydrogenase 1A3 and GABA Metabolism in Breast Cancer Metastasis","volume":"18","author":"Dahn","year":"2022","journal-title":"Metabolomics"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Gupta, N., and Srivastava, S.K. (2021). Atovaquone Suppresses the Growth of Metastatic Triple-Negative Breast Tumors in Lungs and Brain by Inhibiting Integrin\/FAK Signaling Axis. Pharmaceuticals, 14.","DOI":"10.3390\/ph14060521"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Hamester, F., St\u00fcrken, C., Legler, K., Eylmann, K., M\u00f6ller, K., Ro\u00dfberg, M., Gorzelanny, C., Bauer, A.T., Windhorst, S., and Schmalfeldt, B. (2022). Key Role of Hyaluronan Metabolism for the Development of Brain Metastases in Triple-Negative Breast Cancer. Cells, 11.","DOI":"10.3390\/cells11203275"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1158\/0008-5472.CAN-15-1233","article-title":"Penfluridol: An Antipsychotic Agent Suppresses Metastatic Tumor Growth in Triple-Negative Breast Cancer by Inhibiting Integrin Signaling Axis","volume":"76","author":"Ranjan","year":"2016","journal-title":"Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.omto.2021.02.014","article-title":"Involvement of Actin Cytoskeletal Modifications in the Inhibition of Triple-Negative Breast Cancer Growth and Metastasis by Nimbolide","volume":"20","author":"Arumugam","year":"2021","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Vaidya, A., Wang, H., Qian, V., Gilmore, H., and Lu, Z.-R. (2020). Overexpression of Extradomain-B Fibronectin Is Associated with Invasion of Breast Cancer Cells. Cells, 9.","DOI":"10.3390\/cells9081826"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10549-019-05347-0","article-title":"Syndecan-1 Facilitates Breast Cancer Metastasis to the Brain","volume":"178","author":"Sayyad","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/emmm.201303373","article-title":"ADAM8 Expression in Invasive Breast Cancer Promotes Tumor Dissemination and Metastasis","volume":"6","author":"Romagnoli","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Fontana, F., Esser, A.K., Egbulefu, C., Karmakar, P., Su, X., Allen, J.S., Xu, Y., Davis, J.L., Gabay, A., and Xiang, J. (2023). Transferrin Receptor in Primary and Metastatic Breast Cancer: Evaluation of Expression and Experimental Modulation to Improve Molecular Targeting. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0293700"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s43018-021-00297-3","article-title":"Astrocytic Laminin-211 Drives Disseminated Breast Tumor Cell Dormancy in Brain","volume":"3","author":"Dai","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s12195-021-00710-y","article-title":"Evaluating the Role of IL-1\u03b2 in Transmigration of Triple Negative Breast Cancer Cells Across the Brain Endothelium","volume":"15","author":"Motallebnejad","year":"2022","journal-title":"Cell. Mol. Bioeng."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1158\/1078-0432.CCR-15-1836","article-title":"Alterations in Pericyte Subpopulations Are Associated with Elevated Blood\u2013Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer","volume":"22","author":"Lyle","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s40478-023-01646-2","article-title":"Inflammasome Activation in Peritumoral Astrocytes Is a Key Player in Breast Cancer Brain Metastasis Development","volume":"11","author":"Fazakas","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Llevenes, P. (2024). Abstract PO1-06-13: Plasma Exosomes in Obesity-Driven Diabetes Exacerbate Progression of Triple Negative Breast Cancer: Insights from Animal Models. Cancer Res., 84.","DOI":"10.1158\/1538-7445.SABCS23-PO1-06-13"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"DMM034850","DOI":"10.1242\/dmm.034850","article-title":"Identification of Brain Metastasis Genes and Therapeutic Evaluation of Histone Deacetylase Inhibitors in a Clinically Relevant Model of Breast Cancer Brain Metastasis","volume":"11","author":"Kim","year":"2018","journal-title":"Dis. Model. Mech."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Stirling, E., Mackert, J., Bronson, S., Wilson, A., Kooshki, M., Zhao, D., Triozzi, P., Lesser, G., and Soto-Pantoja, D. (2022). 492 SIRP\u03b1 Blockade Results in Tumor Intrinsic and Immune Microenvironment Effects Resulting in the Inhibition of Breast-to-Brain Metastasis. Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd.","DOI":"10.1136\/jitc-2022-SITC2022.0492"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"10233","DOI":"10.1111\/jcmm.15639","article-title":"Obesity and Triple-Negative-Breast-Cancer: Is Apelin a New Key Target?","volume":"24","author":"Gourgue","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13058-022-01514-2","article-title":"Breast Cancer Metastasis to Brain Results in Recruitment and Activation of Microglia through Annexin-A1\/Formyl Peptide Receptor Signaling","volume":"24","author":"Foo","year":"2022","journal-title":"Breast Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Dunn, J., McCuaig, R.D., Tan, A.H.Y., Tu, W.J., Wu, F., Wagstaff, K.M., Zafar, A., Ali, S., Diwakar, H., and Dahlstrom, J.E. (2022). Selective Targeting of Protein Kinase C (PKC)-\u03b8 Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8+ T Cells in Immunotherapy-Resistant and Metastatic Cancers. Cancers, 14.","DOI":"10.3390\/cancers14061596"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"P4-04\u201304","DOI":"10.1158\/1538-7445.SABCS14-P4-04-04","article-title":"Abstract P4-04-04: Estrogen Signaling through Astrocytes Promotes Migration and Invasion of ER-Negative Brain Metastatic Breast Cancer Cells","volume":"75","author":"Cittelly","year":"2015","journal-title":"Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1038\/s41388-019-0756-z","article-title":"Estradiol Induces BDNF\/TrkB Signaling in Triple-Negative Breast Cancer to Promote Brain Metastases","volume":"38","author":"Day","year":"2019","journal-title":"Oncogene"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"102687","DOI":"10.1016\/j.plefa.2025.102687","article-title":"Linoleic Acid Promotes Mammary Tumor Growth and Metastasis to Brain and Lung in Female Balb\/cJ Mice","volume":"206","author":"Salazar","year":"2025","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1038\/onc.2015.353","article-title":"Estrogen Promotes the Brain Metastatic Colonization of Triple Negative Breast Cancer Cells via an Astrocyte-Mediated Paracrine Mechanism","volume":"35","author":"Sartorius","year":"2016","journal-title":"Oncogene"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3892\/ijmm.2017.3060","article-title":"Progesterone Suppresses Triple-Negative Breast Cancer Growth and Metastasis to the Brain via Membrane Progesterone Receptor \u03b1","volume":"40","author":"Zhou","year":"2017","journal-title":"Int. J. Mol. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"114826","DOI":"10.1016\/j.bios.2022.114826","article-title":"A Bioluminescent-Based Probe for in Vivo Non-Invasive Monitoring of Nicotinamide Riboside Uptake Reveals a Link between Metastasis and NAD+ Metabolism","volume":"220","author":"Maric","year":"2023","journal-title":"Biosens. Bioelectron."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/1078-0432.CCR-13-1255","article-title":"\u03b1B-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain","volume":"20","author":"Malin","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1200\/jco.2011.29.15_suppl.2041","article-title":"AlphaB-Crystallin (aBC) Expression in Breast Cancer Brain Metastases (BM) and Primary Breast Cancer (pBC) with Eventual BM and Association with Outcome","volume":"29","author":"Adamo","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41523-024-00656-0","article-title":"Targeting Fatty Acid Synthase in Preclinical Models of TNBC Brain Metastases Synergizes with SN-38 and Impairs Invasion","volume":"10","author":"Serhan","year":"2024","journal-title":"npj Breast Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10585-016-9832-8","article-title":"Dutch Distant Breast Cancer Metastases Consortium. The Prognostic Effect of DDX3 Upregulation in Distant Breast Cancer Metastases","volume":"34","author":"Schrijver","year":"2017","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Vogel-Gonz\u00e1lez, M., Musa-Afaneh, D., Rivera Gil, P., and Vicente, R. (2021). Zinc Favors Triple-Negative Breast Cancer\u2019s Microenvironment Modulation and Cell Plasticity. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179188"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.clinimag.2017.10.016","article-title":"Magnetic Resonance (MR) Features in Triple Negative Breast Cancer (TNBC) vs Receptor Positive Cancer (NTNBC)","volume":"49","author":"Angelini","year":"2018","journal-title":"Clin. Imaging"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Zaryouh, H., Van Loenhout, J., Peeters, M., Vermorken, J.B., Lardon, F., and Wouters, A. (2022). Co-Targeting the EGFR and PI3K\/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?. Cancers, 14.","DOI":"10.3390\/cancers14246128"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Wee, P., and Wang, Z. (2017). Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers, 9.","DOI":"10.3390\/cancers9050052"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Littlefield, P., Liu, L., Mysore, V., Shan, Y., Shaw, D.E., and Jura, N. (2014). Structural Analysis of the EGFR\/Her3 Heterodimer Reveals the Molecular Basis for Activating HER3 Mutations. Sci. Signal., 7.","DOI":"10.1126\/scisignal.2005786"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13058-015-0547-6","article-title":"The Clinical and Functional Significance of C-Met in Breast Cancer: A Review","volume":"17","author":"Jones","year":"2015","journal-title":"Breast Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"102140","DOI":"10.1016\/j.tranon.2024.102140","article-title":"The PIK3CA Gene and Its Pivotal Role in Tumor Tropism of Triple-Negative Breast Cancer","volume":"50","author":"Mallick","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1158\/1078-0432.CCR-10-3339","article-title":"Dual Blockade of EGFR and C-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells","volume":"17","author":"Xu","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/1477-3163.44372","article-title":"Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer","volume":"7","author":"Puri","year":"2008","journal-title":"J. Carcinog."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1091\/mbc.e13-08-0434","article-title":"The SHCD Signaling Adaptor Facilitates Ligand-Independent Phosphorylation of the EGF Receptor","volume":"25","author":"Wills","year":"2014","journal-title":"Mol. Biol. Cell"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Rascio, F., Spadaccino, F., Rocchetti, M.T., Castellano, G., Stallone, G., Netti, G.S., and Ranieri, E. (2021). The Pathogenic Role of PI3K\/Akt Pathway in Cancer Onset and Drug Resistance: An Updated Review. Cancers, 13.","DOI":"10.3390\/cancers13163949"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Cai, Y.-C., Yang, H., Wang, K.-F., Chen, T.-H., Jiang, W.-Q., and Shi, Y.-X. (2020). ANGPTL4 Overexpression Inhibits Tumor Cell Adhesion and Migration and Predicts Favorable Prognosis of Triple-Negative Breast Cancer. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07343-w"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1093\/nar\/gkae233","article-title":"Arid1a Regulates DNA Repair through Chromatin Organization and Its Deficiency Triggers DNA Damage-Mediated Anti-Tumor Immune Response","volume":"52","author":"Bakr","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/cac2.12465","article-title":"Low Level of Arid1a Contributes to Adaptive Immune Resistance and Sensitizes Triple-negative Breast Cancer to Immune Checkpoint Inhibitors","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"eabd2712","DOI":"10.1126\/sciadv.abd2712","article-title":"Revisiting the PD-1 Pathway","volume":"6","author":"Patsoukis","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: An Attractive Target for Antibody-Based Immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Zolota, V., Tzelepi, V., Piperigkou, Z., Kourea, H., Papakonstantinou, E., Argentou, M.-I., and Karamanos, N.K. (2021). Epigenetic Alterations in Triple-Negative Breast Cancer\u2014the Critical Role of Extracellular Matrix. Cancers, 13.","DOI":"10.3390\/cancers13040713"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12964-019-0486-4","article-title":"FGFR3 Signaling and Function in Triple Negative Breast Cancer","volume":"18","author":"Chew","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"98","DOI":"10.38212\/2224-6614.3090","article-title":"Quercetin Blocks the Aggressive Phenotype of Triple Negative Breast Cancer by Inhibiting IGF1\/IGF1R-Mediated EMT Program","volume":"29","author":"Chen","year":"2021","journal-title":"J. Food Drug Anal."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Liang, Z., Mo, Y., Zhang, Y., Yu, Y., and Ji, Y. (2025). Molecular Mechanisms and Signaling Pathways Related to Brain Metastasis in Breast Cancer. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1585668"},{"key":"ref_159","unstructured":"National Library of Medicine (U.S.) (2026, January 30). Safety and Feasibility of Focused Ultrasound-Enabled Liquid Biopsy in Patients with Brain Tumours. Identifier NCT04940507, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04940507?tab=researcher."},{"key":"ref_160","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Pivotal Study to Evaluate the Safety and Effectiveness of Exablate Model 4000 Using Microbubble Resonators to Temporarily Mediate Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors. Identifier NCT05383872, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT05383872."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"ii45","DOI":"10.1093\/noajnl\/vdac015","article-title":"Circulating tumor cells and extracellular vesicles as liquid biopsy markers in neuro-oncology: Prospects and limitations","volume":"4","author":"Westphal","year":"2022","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"105748","DOI":"10.1016\/j.ebiom.2025.105748","article-title":"An ANGPTL4 Inhibitory Antibody Safely Improves Lipid Profiles in Non-Human Primates","volume":"117","author":"Cummings","year":"2025","journal-title":"eBioMedicine"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(25)00825-6","article-title":"Safety and Efficacy of a Novel ANGPTL4 Inhibitory Antibody for Lipid Lowering: Results from Phase 1 and Phase 1B\/2A Clinical Studies","volume":"405","author":"Cummings","year":"2025","journal-title":"Lancet"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Ramos, P., Shi, Q., Kleberg, J., Maharjan, C.K., Zhang, W., and Kolb, R. (2025). ANGPTL4: A Comprehensive Review of 25 Years of Research. Cancers, 17.","DOI":"10.3390\/cancers17142364"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1242\/jcs.079236","article-title":"A Competitive Hexapeptide Inhibitor of Annexin A2 Prevents Hypoxia-Induced Angiogenic Events","volume":"124","author":"Valapala","year":"2011","journal-title":"J. Cell Sci."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e011716","DOI":"10.1136\/jitc-2025-011716","article-title":"Targeting Annexin A2 to Reactivate Tumor-Associated Antigens Presentation and Relieve Immune Tolerance in Liver Cancer","volume":"13","author":"Tang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41565-025-01867-7","article-title":"Systemic HER3 ligand-mimicking nanobioparticles enter the brain and reduce intracranial tumour growth","volume":"20","author":"Mikhael","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s12951-025-03415-w","article-title":"Advances in brain-targeted delivery strategies and natural product-mediated enhancement of blood-brain barrier permeability","volume":"23","author":"Liu","year":"2025","journal-title":"J. Nanobiotechnology"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1021\/acsmedchemlett.9b00599","article-title":"Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors","volume":"11","author":"Tsang","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/ajh.24099","article-title":"Azacitidine Treatment for Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 3q Abnormalities","volume":"90","author":"Wanquet","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"104910","DOI":"10.1016\/j.critrevonc.2025.104910","article-title":"Targeting Cancer Metabolism: Therapeutic Potential of the Fatty Acid Synthase (FASN) Inhibitors","volume":"214","author":"Nuzzo","year":"2025","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e13077","DOI":"10.1200\/JCO.2023.41.16_suppl.e13077","article-title":"Inhibition of FASN as a Potential Treatment of Advanced Endocrine Therapy-Resistant Breast Cancer","volume":"41","author":"Gunuganti","year":"2023","journal-title":"JCO"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"5810","DOI":"10.1158\/1078-0432.CCR-21-0493","article-title":"Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC","volume":"27","author":"Sardesai","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10549-013-2473-6","article-title":"Targeting HMG-CoA Reductase with Statins in a Window-of-Opportunity Breast Cancer Trial","volume":"138","author":"Bjarnadottir","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12967-015-0486-0","article-title":"Statin-Induced Anti-Proliferative Effects via Cyclin D1 and P27 in a Window-of-Opportunity Breast Cancer Trial","volume":"13","author":"Feldt","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Kamal, A., Boerner, J., Assad, H., Chen, W., and Simon, M.S. (2024). The Effect of Statins on Markers of Breast Cancer Proliferation and Apoptosis in Women with In Situ or Early-Stage Invasive Breast Cancer. IJMS, 25.","DOI":"10.3390\/ijms25179587"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","article-title":"Ipatasertib plus Paclitaxel versus Placebo plus Paclitaxel as First-Line Therapy for Metastatic Triple-Negative Breast Cancer (LOTUS): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"18","author":"Kim","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1078-0432.CCR-21-2498","article-title":"Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer","volume":"28","author":"Shi","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1158\/1078-0432.CCR-23-2084","article-title":"First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results","volume":"30","author":"Schmid","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.2024.42.16_suppl.1094","article-title":"Efficacy and Genomic Analysis of HER2 -Mutant, Metastatic Triple-Negative Breast Cancer Treated wi th Neratinib Alone or in Combination with Trastuzumab in the Phase 2 SUMMIT Basket Trial","volume":"42","author":"Jhaveri","year":"2024","journal-title":"JCO"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13058-020-01354-y","article-title":"Phase 2 Study of Buparlisib (BKM120), a Pan-Class I PI3K Inhibitor, in Patients with Metastatic Triple-Negative Breast Cancer","volume":"22","author":"Saura","year":"2020","journal-title":"Breast Cancer Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1158\/1078-0432.CCR-21-3078","article-title":"Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer","volume":"28","author":"Radovich","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"TPS1128","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS1128","article-title":"A Phase I\/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination with Copanlisib in Patients with Metastatic Triple-Negative Breast Cancer (TNBC)","volume":"40","author":"Bagegni","year":"2022","journal-title":"JCO"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","article-title":"Molecular Alterations in Triple-Negative Breast Cancer-the Road to New Treatment Strategies","volume":"389","author":"Denkert","year":"2017","journal-title":"Lancet"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1470-2045(24)00737-X","article-title":"Darolutamide or Capecitabine in Triple-Negative, Androgen Receptor-Positive, Advanced Breast Cancer (UCBG 3-06 START): A Multicentre, Non-Comparative, Randomised, Phase 2 Trial","volume":"26","author":"Bonnefoi","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"TPS1142","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS1142","article-title":"TBCRC 058: A Randomized Phase II Study of Enzalutamide, Enzalutamide with Mifepristone, and Treatment of Physician\u2019s Choice in Patients with Androgen Receptor-Positive Metastatic Triple-Negative or Estrogen Receptor-Low Breast Cancer (NCT06099769)","volume":"43","author":"Traina","year":"2025","journal-title":"JCO"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"TPS2671","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2671","article-title":"ATTAINMENT: A Phase Ib Trial of MDX-124, a First-in-Class Annexin-A1 Targeting Antibody, Alone and in Combination with Anti-Cancer Treatments, in Patients with Advanced Solid Tumors","volume":"42","author":"Palmer","year":"2024","journal-title":"JCO"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1200\/JCO.2021.39.15_suppl.5566","article-title":"Phase 1b Study of GAS6\/AXL Inhibitor (AVB-500) in Recurrent, Platinum-Resistant Ovarian Carcinoma","volume":"39","author":"Fuh","year":"2021","journal-title":"JCO"},{"key":"ref_189","unstructured":"National Library of Medicine (U.S.) (2026, January 30). Impact of Beta-2 Adrenergic Blockade With Checkpoint Inhibition in Checkpoint Inhibitor Refractory Metastatic Triple Negative Breast Cancer. Identifier NCT05741164, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05741164."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"O8","DOI":"10.1186\/2051-1426-3-S2-O8","article-title":"Interim Results of an Ongoing Phase I, Dose Escalation Study of MGA271 (Fc-Optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3","volume":"3","author":"Powderly","year":"2015","journal-title":"J Immunother Cancer"},{"key":"ref_191","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Phase 1\/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti-PD-1 Antibody) in Patients with Advanced Solid Tumors. Identifier NCT03729596, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03729596?term=b7-h3&cond=triple%20negative%20breast%20cancer&rank=3."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.23.02225","article-title":"Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline","volume":"42","author":"Bedrosian","year":"2024","journal-title":"JCO"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"TPS619","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS619","article-title":"Partner Research Team. PARTNER: A Randomized, Phase II\/III Trial to Evaluate the Safety and Efficacy of the Addition of Olaparib to Platinum-Based Neoadjuvant Chemotherapy in Patients with Triple-Negative and\/or Germline BRCA-Mutated Breast Cancer","volume":"40","author":"Drewett","year":"2022","journal-title":"JCO"},{"key":"ref_194","unstructured":"National Library of Medicine (U.S.) (2026, January 30). Phase 1 Study of Autologous Tris-CAR-T Cell Locoregional Immunotherapy for Recurrent Glioblastoma. Identifier NCT05577091, 2024, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05577091."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/annonc\/mdp314","article-title":"An Open-Label, Randomized Phase II Study of Adecatumumab, a Fully Human Anti-EpCAM Antibody, as Monotherapy in Patients with Metastatic Breast Cancer","volume":"21","author":"Schmidt","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1200\/JCO.2023.41.16_suppl.4034","article-title":"EpCAM CAR T (IMC001) for the Treatment of Advanced GI Cancers","volume":"41","author":"Luo","year":"2023","journal-title":"JCO"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"e15008","DOI":"10.1200\/JCO.2024.42.16_suppl.e15008","article-title":"BC3195, a Novel ADC Targeting CDH3: Preliminary Results of a First-in-Human Phase I Study in Patients with Advanced Solid Malignancies","volume":"42","author":"Chen","year":"2024","journal-title":"JCO"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1158\/1535-7163.MCT-21-0652","article-title":"A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients with Solid Tumors","volume":"21","author":"Duca","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_199","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Phase Ib\/II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Glumetinib (SCC244), a Selective MET Inhibitor in Patients with Advanced Non-Small Cell Lung Cancer Harboring MET-alterations. Identifier NCT04270591, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04270591."},{"key":"ref_200","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Phase III, Randomised, Open-Label Study of Savolitinib in Combination with Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants with EGFR Mutated, MET-Overexpressed and\/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON). Identifier NCT05261399, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05261399."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Nwagwu, C.D., Immidisetti, A.V., Bukanowska, G., Vogelbaum, M.A., and Carbonell, A.-M. (2020). Convection-Enhanced Delivery of a First-in-Class Anti-\u0152\u00ed1 Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13010040"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10549-016-3812-1","article-title":"Canadian Cancer Trials Group IND197: A Phase II Study of Foretinib in Patients with Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2-Negative Recurrent or Metastatic Breast Cancer","volume":"157","author":"Rayson","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1634\/theoncologist.2016-0229","article-title":"Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients","volume":"22","author":"Tolaney","year":"2017","journal-title":"Oncologist"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"TPS3162","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3162","article-title":"Phase 1b Study Evaluating the Efficacy and Safety of ABBV-400, a c-Met-Targeting Antibody-Drug Conjugate, in Select Advanced Solid Tumor Indications","volume":"42","author":"Perets","year":"2024","journal-title":"JCO"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"80046","DOI":"10.18632\/oncotarget.11098","article-title":"First-in-Human Phase I Clinical Trial of RG7356, an Anti-CD44 Humanized Antibody, in Patients with Advanced, CD44-Expressing Solid Tumors","volume":"7","author":"Coveler","year":"2016","journal-title":"Oncotarget"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"e15010","DOI":"10.1200\/JCO.2024.42.16_suppl.e15010","article-title":"Preliminary Results from a First-in-Human Trial of AMT-116, a Topoisomerase I Inhibitor Containing Antibody-Drug Conjugate (ADC), in Patients with Advanced Solid Tumors","volume":"42","author":"Coward","year":"2024","journal-title":"JCO"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"TPS2681","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS2681","article-title":"Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) with Anti-PD-1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors","volume":"39","author":"Karapetyan","year":"2021","journal-title":"JCO"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"43375","DOI":"10.18632\/oncotarget.6234","article-title":"Targeting CXCR1 on Breast Cancer Stem Cells: Signaling Pathways and Clinical Application Modelling","volume":"6","author":"Brandolini","year":"2015","journal-title":"Oncotarget"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.7150\/thno.15625","article-title":"Role of the CXCL8-CXCR1\/2 Axis in Cancer and Inflammatory Diseases","volume":"7","author":"Ha","year":"2017","journal-title":"Theranostics"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.clbc.2016.03.005","article-title":"Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study","volume":"16","author":"Wisinski","year":"2016","journal-title":"Clin. Breast Cancer"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","article-title":"Camizestrant, a next-Generation Oral SERD, versus Fulvestrant in Post-Menopausal Women with Oestrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer (SERENA-2): A Multi-Dose, Open-Label, Randomised, Phase 2 Trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_212","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A First-in-Human, Open-Label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors. Identifier NCT05720117, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05720117."},{"key":"ref_213","unstructured":"National Library of Medicine (U.S.) (2026, January 30). Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of WSD0922-FU. Identifier NCT04197934, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04197934."},{"key":"ref_214","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel. Identifier NCT03218826, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03218826."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1535-7163.MCT-15-0419","article-title":"R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis","volume":"14","author":"Guo","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_216","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Phase 2 Study of Senaparib in Combination with Temozolomide in ARID1A Mutation Associated Ovarian Cancer. Identifier NCT06617923, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06617923?term=arid1a&rank=8."},{"key":"ref_217","unstructured":"National Library of Medicine (U.S.) (2026, January 30). Phase II Study of ROS1 Targeting with Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours. Identifier NCT03620643, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03620643?term=CDH1&cond=triple%20negative%20breast%20cancer&rank=1."},{"key":"ref_218","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexander Disease. Identifier NCT04849741, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04849741."},{"key":"ref_219","unstructured":"National Library of Medicine (U.S.) (2026, January 30). Evaluation of 4-Methylumbelliferone for Treatment of Chronic Hepatitis B (HBV) and Chronic Hepatitis C (HCV). Identifier NCT00225537, 2006, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00225537."},{"key":"ref_220","unstructured":"National Library of Medicine (U.S.) (2026, January 30). An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin\/Paclitaxel Plus Pembrolizumab Compared with Pembrolizumab in Combination with Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive\/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03). Identifier NCT06797635, 2026, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06797635."},{"key":"ref_221","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Phase 1\/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers. Identifier NCT06596694, 2026, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06596694."},{"key":"ref_222","unstructured":"National Library of Medicine (U.S.) (2026, January 30). Efficacy and Safety of Pyrotinib in Combination with Neoadjuvant Chemotherapy in Stage II-III HR+\/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II, Single-center, Randomized, Double-Blinded, Placebo-Controlled Trial. Identifier NCT04872985, 2026, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04872985."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00280-013-2362-z","article-title":"Pilot Trial of EZN-2968, an Antisense Oligonucleotide Inhibitor of Hypoxia-Inducible Factor-1 Alpha (HIF-1\u0152\u00b1), in Patients with Refractory Solid Tumors","volume":"73","author":"Jeong","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref_224","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults with Advance Solid Tumors. Identifier NCT01120288, 2018, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01120288."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional Delivery of IL-13R\u0152\u00b12-Targeting CAR-T Cells in Recurrent High-Grade Glioma: A Phase 1 Trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"key":"ref_226","unstructured":"National Library of Medicine (U.S.) (2026, January 30). Pilot Feasibility and Safety Study of Cellular Immunotherapy for Recurrent\/Refractory Malignant Glioma Using Genetically-Modified Autologous CD8+ T Cell Clones. Identifier NCT00730613, 2017, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00730613."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/neuonc\/nou045","article-title":"Significance of Interleukin-13 Receptor Alpha 2-Targeted Glioblastoma Therapy","volume":"16","author":"Thaci","year":"2014","journal-title":"Neuro-Oncol."},{"key":"ref_228","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors. Identifier NCT04389632, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04389632."},{"key":"ref_229","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants with Advanced Solid Tumors. Identifier NCT07090499, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07090499."},{"key":"ref_230","unstructured":"National Library of Medicine (U.S.) (2026, January 30). Phase 1b\/2 Trial of Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients with Brain Metastases from Cutaneous Melanoma. Identifier NCT06194929, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06194929."},{"key":"ref_231","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Phase 2 Study of VS-6766 (Dual RAF\/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK). Identifier NCT05512208, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05512208."},{"key":"ref_232","unstructured":"National Library of Medicine (U.S.) (2026, January 30). GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II\/III Response Adaptive Randomization Platform Trial Designed to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GBM. Identifier NCT03970447, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03970447."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/annonc\/mdy244","article-title":"First-in-Human Study of LY3039478, an Oral Notch Signaling Inhibitor in Advanced or Metastatic Cancer","volume":"29","author":"Massard","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1158\/1078-0432.CCR-14-0809","article-title":"Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer","volume":"21","author":"Previs","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"TPS450","DOI":"10.1200\/JCO.2021.39.3_suppl.TPS450","article-title":"MEKiAUTO: A Phase I\/II Open-Label Study of Combination Therapy with the MEK Inhibitor Cobimetinib, Immune-Checkpoint Blockade with Atezolizumab, and the AUTOphagy Inhibitor Hydroxychloroquine in KRAS -Mutated Advanced Malignancies","volume":"39","author":"Raufi","year":"2021","journal-title":"JCO"},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Bestion, E., Raymond, E., Mezouar, S., and Halfon, P. (2023). Update on Autophagy Inhibitors in Cancer: Opening up to a Therapeutic Combination with Immune Checkpoint Inhibitors. Cells, 12.","DOI":"10.3390\/cells12131702"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"e15088","DOI":"10.1200\/JCO.2023.41.16_suppl.e15088","article-title":"A Phase 2 Basket Trial of an ERK1\/2 Inhibitor (LY3214996) in Combination with Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MAP2K1\/2 ERK1\/2, and NF1","volume":"41","author":"Taza","year":"2023","journal-title":"JCO"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2023.03.009","article-title":"Uterine Leiomyosarcomas Harboring MAP2K4 Gene Amplification Are Sensitive in Vivo to PLX8725, a Novel MAP2K4 Inhibitor","volume":"172","author":"McNamara","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.23.01680","article-title":"Improved Survival with Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA -Activated Stage III Colon Cancer: CALGB\/SWOG 80702 (Alliance)","volume":"42","author":"Nowak","year":"2024","journal-title":"JCO"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jamaoncol.2021.2193","article-title":"Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients with Breast Cancer: The REACT Randomized Clinical Trial","volume":"7","author":"Coombes","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1200\/JCO.18.00636","article-title":"Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial","volume":"37","author":"Hamy","year":"2019","journal-title":"JCO"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/bcr3409","article-title":"A Randomised Controlled Phase II Trial of Pre-Operative Celecoxib Treatment Reveals Anti-Tumour Transcriptional Response in Primary Breast Cancer","volume":"15","author":"Veeck","year":"2013","journal-title":"Breast Cancer Res."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10637-019-00754-y","article-title":"A Phase I, Dose-Escalation Study of PF-06650808, an Anti-Notch3 Antibody-Drug Conjugate, in Patients with Breast Cancer and Other Advanced Solid Tumors","volume":"38","author":"Rosen","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s10637-018-0714-6","article-title":"A Phase 1 Dose Escalation and Expansion Study of Tarextumab (OMP-59R5) in Patients with Solid Tumors","volume":"37","author":"Smith","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Moore, G., Annett, S., McClements, L., and Robson, T. (2020). Top Notch Targeting Strategies in Cancer: A Detailed Overview of Recent Insights and Current Perspectives. Cells, 9.","DOI":"10.3390\/cells9061503"},{"key":"ref_246","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with Germline BRCA1\/2 Mutations. Identifier NCT02000622, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02000622."},{"key":"ref_247","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A PHASE 3, OPEN-LABEL, RANDOMIZED PARALLEL, 2-ARM, MULTI-CENTER STUDY OF TALAZOPARIB(BMN 673) VERSUS PHYSICIAN\u2019S CHOICE IN GERMLINE BRCA MUTATION SUBJECTS WITH LOCALLY ADVANCED AND\/OR METASTATIC BREAST CANCER, WHO HAVE RECEIVED PRIOR CHEMOTHERAPY REGIMENS FOR METASTATIC DISEASE. Identifier NCT01945775, 2022, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01945775."},{"key":"ref_248","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Randomised, Double-blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with gBRCA1\/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy. Identifier NCT02032823, 2026, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02032823."},{"key":"ref_249","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer\u2014(KEYNOTE-355). Identifier NCT02819518, 2024, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02819518."},{"key":"ref_250","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Nab-Paclitaxel Compared with Placebo with Nab-Paclitaxel for Patients with Previously Untreated Metastatic Triple-Negative Breast Cancer. Identifier NCT02425891k, 2022, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02425891."},{"key":"ref_251","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) in Combination with Paclitaxel Compared with Placebo With Paclitaxel for Patients With Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer. Identifier NCT03125902, 2024, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03125902."},{"key":"ref_252","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Phase III Randomized, Double Blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer. Identifier NCT01234337, 2018, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01234337."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/1535-7163.MCT-19-0098","article-title":"Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071","volume":"19","author":"Larkin","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_254","doi-asserted-by":"crossref","unstructured":"Bauer, S., Larkin, J., Hodi, F.S., Stephen, F., Kapiteijn, E.H.W., Schwartz, G.K., Calvo, E., Yerramilli-Rao, P., Piperno-Neumann, S., and Carvajal, R.D. (2023). A Phase Ib Trial of Combined PKC and MEK Inhibition with Sotrastaurin and Binimetinib in Patients with Metastatic Uveal Melanoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.975642"},{"key":"ref_255","doi-asserted-by":"crossref","unstructured":"Shoushtari, A.N., Khan, S., Komatsubara, K., Feun, L., Acquavella, N., Singh-Kandah, S., Negri, T., Nesson, A., Abbate, K., and Cremers, S. (2021). A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3K\u0152\u00b1 Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13215504"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1158\/1078-0432.CCR-22-2060","article-title":"Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial","volume":"29","author":"Saldain","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/1078-0432.CCR-19-0443","article-title":"Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate","volume":"26","author":"Lee","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2022.40.16_suppl.3084","article-title":"Phase 1 Results of a Phase 1\/2 Trial of CYT-0851, a First-in-Class Inhibitor of RAD51-Mediated Homologous Recombination, in Patients with Advanced Solid and Hematologic Cancers","volume":"40","author":"Lynch","year":"2022","journal-title":"JCO"},{"key":"ref_259","unstructured":"National Library of Medicine (U.S.) (2026, January 30). BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation. Identifier NCT04711109, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04711109."},{"key":"ref_260","unstructured":"National Library of Medicine (U.S.) (2026, January 30). Randomized Clinical Trial of RANKL Inhibition with Denosumab on Mammographic Density in Premenopausal Women with Dense Breasts (TRIDENT). Identifier NCT04067726, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04067726."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1200\/JCO.2021.39.15_suppl.2623","article-title":"Safety, Pharmacokinetics, Efficacy, and Preliminary Biomarker Data of First-in-Class BI 765063, a Selective SIRP\u0152\u00b1 Inhibitor: Results of Monotherapy Dose Escalation in Phase 1 Study in Patients with Advanced Solid Tumors","volume":"39","author":"Champiat","year":"2021","journal-title":"JCO"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s10555-025-10269-z","article-title":"Novel Immunotherapy for Gastric Cancer: Targeting the CD47-SIRP\u0152\u00b1 Axis","volume":"44","author":"Ooki","year":"2025","journal-title":"Cancer Metastasis Rev."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"712","DOI":"10.4049\/jimmunol.2001019","article-title":"Novel SIRP\u0152\u00b1 Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells While Preserving T Cells","volume":"206","author":"Andrejeva","year":"2021","journal-title":"J. Immunol."},{"key":"ref_264","unstructured":"National Library of Medicine (U.S.) (2026, January 30). Phase I Study of Autologous CAR T-Cells Targeting the CD138 Antigen for Relapsed or Refractory Multiple Myeloma. Identifier NCT03672318, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03672318."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"JCO"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(22)00403-3","article-title":"Eprenetapopt Combined with Venetoclax and Azacitidine in TP53-Mutated Acute Myeloid Leukaemia: A Phase 1, Dose-Finding and Expansion Study","volume":"10","author":"Goldberg","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53 -Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"JCO"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1200\/JCO.2023.41.16_suppl.3514","article-title":"Phase 1 Study of WNT Pathway Porcupine Inhibitor CGX1321 and Phase 1b Study of CGX1321 + Pembrolizumab (Pembro) in Patients (Pts) with Advanced Gastrointestinal (GI) Tumors","volume":"41","author":"Giannakis","year":"2023","journal-title":"JCO"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"e15138","DOI":"10.1200\/JCO.2023.41.16_suppl.e15138","article-title":"GSK-3 Inhibitor Elraglusib (9-ING-41) to Enhance Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergize with Anti-PD-L1 in a Murine Model of Colorectal Cancer","volume":"41","author":"Huntington","year":"2023","journal-title":"JCO"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"19977","DOI":"10.1038\/s41598-019-56461-4","article-title":"9-ING-41, a Small Molecule Inhibitor of GSK-3beta, Potentiates the Effects of Anticancer Therapeutics in Bladder Cancer","volume":"9","author":"Kuroki","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_271","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Phase IIa, Randomized, Double-blind, Placebo-controlled, Exploratory, Dose-ranging Study to Evaluate the Safety, Effectiveness and Pharmacokinetics of Three Courses of DC-TAB Treatment in Patients with Multiple Sclerosis. Identifier NCT02442570, 2015, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02442570?term=NCT02442570&rank=1."},{"key":"ref_272","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Randomized, Double -Blind (Sponsor-Open), Placebo-Controlled Study to Assess the Effect of NT-0796 on Inflammation in Obese Participants at Risk of Cardiovascular Disease. Identifier NCT06129409, 2024, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06129409?term=NT0796&rank=1."},{"key":"ref_273","unstructured":"National Library of Medicine (U.S.) (2026, January 30). A Randomized, Double-Blind, Placebo-Controlled, Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients with Mild to Moderate Parkinson\u2019s Disease. Identifier NCT06822517, 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06822517?term=VENT-02&rank=1."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1909\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T14:59:11Z","timestamp":1771253951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":273,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27041909"],"URL":"https:\/\/doi.org\/10.3390\/ijms27041909","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]}}}